华仁药业(300110) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥385,486,122.57, representing a 12.27% increase compared to ¥343,348,482.94 in the same period last year[2] - Net profit attributable to shareholders was ¥25,039,647.36, a slight increase of 0.86% from ¥24,826,733.26 year-on-year[2] - Net profit for Q1 2022 reached CNY 26,181,499.72, a slight increase from CNY 25,609,037.86 in Q1 2021, representing a growth of 2.2%[19] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0212, compared to CNY 0.0210 in Q1 2021[20] Cash Flow - The net cash flow from operating activities improved significantly to ¥4,303,756.31, compared to a negative cash flow of ¥552,463,544.34 in the previous year, marking a 100.78% change[2] - Cash inflow from operating activities was CNY 572,457,343.81, significantly higher than CNY 351,286,075.28 in the previous year, marking a growth of 63.0%[21] - The total cash outflow from operating activities was 568,153,587.50 CNY, compared to 903,749,619.62 CNY in the prior year[23] - The net cash flow from investing activities was -10,797,253.91 CNY, compared to -8,351,048.05 CNY in the same period last year[23] - Cash inflow from financing activities was 666,450,000.00 CNY, while cash outflow was 712,010,752.10 CNY, resulting in a net cash flow of -45,560,752.10 CNY[23] - The company paid 696,381,725.52 CNY in debt repayment during the quarter, significantly higher than 311,500,000.00 CNY in the previous year[23] - The company reported a decrease in cash and cash equivalents by 52,056,826.41 CNY during the quarter[23] Assets and Liabilities - The total assets decreased by 5.29% to ¥5,342,879,729.63 from ¥5,641,539,633.06 at the end of the previous year[2] - Total liabilities decreased to CNY 2,873,266,382.16 from CNY 3,198,107,785.31, a reduction of 10.2% year-over-year[18] - The company's total equity increased to CNY 2,469,613,347.47, up from CNY 2,443,431,847.75, reflecting a growth of 1.1%[18] - The total current assets decreased from CNY 3,107,814,323.37 to CNY 2,850,785,919.05, indicating a decline of about 8.3%[15] - Non-current assets decreased from CNY 2,533,725,309.69 to CNY 2,492,093,810.58, a reduction of approximately 1.6%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,377[8] - The top shareholder, Xi'an Qujiang Tian Shou Dajiankang Investment Partnership, holds 20.00% of the shares, totaling 236,442,597 shares[8] - The company has a total of 236,442,597 shares held by Xi'an Qujiang Tianshou Health Investment Partnership, which is the largest shareholder[10] Expenses - Research and development expenses decreased by 34.14% to ¥11,425,222.29 from ¥17,347,504.35 in the same period last year[6] - Management expenses increased by 42.08% to ¥25,821,299.63 from ¥18,174,381.40 year-on-year[6] - The company’s sales expenses rose to CNY 90,185,543.90, an increase of 10.0% compared to CNY 81,961,905.31 in Q1 2021[18] Other Information - The company received government subsidies amounting to ¥2,557,484.05 during the reporting period[4] - The company reported a credit impairment loss of CNY -9,803,882.00, slightly improved from CNY -10,715,206.33 in the previous year[19] - The company reported a total of 1,841,375 shares under lock-up agreements, with 14,000 shares released during the quarter[12] - The company has not disclosed any new product developments or market expansion strategies in this quarter's report[12] - Cash and cash equivalents decreased from CNY 417,151,565.03 to CNY 349,743,081.64, a reduction of about 16.2%[14] - Accounts receivable increased slightly from CNY 802,986,278.87 to CNY 808,653,969.41, showing a growth of approximately 0.8%[14] - Inventory decreased from CNY 275,472,166.97 to CNY 255,300,521.80, reflecting a decline of about 7.3%[15] - Short-term borrowings decreased from CNY 1,578,814,121.21 to CNY 1,439,278,848.94, a reduction of approximately 8.8%[15] - The company did not undergo an audit for the first quarter report[25]